Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 1
1955 4
1958 2
1959 2
1961 1
1962 8
1963 10
1964 10
1965 10
1966 10
1967 10
1968 11
1969 15
1970 14
1971 8
1972 7
1973 2
1974 5
1975 16
1976 7
1977 13
1978 9
1979 10
1980 14
1981 12
1982 12
1983 26
1984 18
1985 24
1986 30
1987 21
1988 23
1989 51
1990 30
1991 35
1992 29
1993 30
1994 20
1995 35
1996 26
1997 39
1998 29
1999 39
2000 32
2001 50
2002 44
2003 44
2004 53
2005 59
2006 43
2007 44
2008 49
2009 55
2010 56
2011 58
2012 76
2013 94
2014 91
2015 66
2016 41
2017 62
2018 65
2019 93
2020 111
2021 120
2022 88
2023 60

Text availability

Article attribute

Article type

Publication date

Search Results

2,101 results

Results by year

Filters applied: . Clear all
Page 1
Role of acyl-CoA synthetase ACSL4 in arachidonic acid metabolism.
Kuwata H, Hara S. Kuwata H, et al. Among authors: hara s. Prostaglandins Other Lipid Mediat. 2019 Oct;144:106363. doi: 10.1016/j.prostaglandins.2019.106363. Epub 2019 Jul 12. Prostaglandins Other Lipid Mediat. 2019. PMID: 31306767 Review.
Effect of Spinal Cord Burst Stimulation vs Placebo Stimulation on Disability in Patients With Chronic Radicular Pain After Lumbar Spine Surgery: A Randomized Clinical Trial.
Hara S, Andresen H, Solheim O, Carlsen SM, Sundstrøm T, Lønne G, Lønne VV, Taraldsen K, Tronvik EA, Øie LR, Gulati AM, Sagberg LM, Jakola AS, Solberg TK, Nygaard ØP, Salvesen ØO, Gulati S. Hara S, et al. JAMA. 2022 Oct 18;328(15):1506-1514. doi: 10.1001/jama.2022.18231. JAMA. 2022. PMID: 36255427 Free PMC article. Clinical Trial.
Foreword.
Hara S. Hara S. Biol Pharm Bull. 2022;45(8):978. doi: 10.1248/bpb.b22-ctf4508. Biol Pharm Bull. 2022. PMID: 35908906 Free article. No abstract available.
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
Sugimoto A, Matsumoto S, Udagawa H, Itotani R, Usui Y, Umemura S, Nishino K, Nakachi I, Kuyama S, Daga H, Hara S, Miyamoto S, Kato T, Sakakibara-Konishi J, Tabata E, Nakagawa T, Kawaguchi T, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Yoh K, Goto K. Sugimoto A, et al. Among authors: hara s. Clin Cancer Res. 2023 Apr 14;29(8):1506-1514. doi: 10.1158/1078-0432.CCR-22-1749. Clin Cancer Res. 2023. PMID: 36201167
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: hara s. Chest. 2022 Nov;162(5):1188-1198. doi: 10.1016/j.chest.2022.05.035. Epub 2022 Jun 1. Chest. 2022. PMID: 35661746
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: hara s. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, Otani S, Shimizu J, Katakami N, Azuma K, Miura N, Nishino K, Hara S, Teraoka S, Morita S, Nakagawa K, Yamamoto N. Akamatsu H, et al. Among authors: hara s. JAMA Oncol. 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758. JAMA Oncol. 2021. PMID: 33410885 Free PMC article. Clinical Trial.
2,101 results